CellCarta Expands CRO Genomics Capabilities Through Pillar Biosciences Alliance

• CellCarta and Pillar Biosciences announced a multi-year global strategic partnership to expand rapid, decentralized tumor profiling for oncology clinical trials.

• The collaboration combines Pillar’s oncoReveal NGS panels with CellCarta’s global CRO laboratory network to accelerate patient enrollment and biomarker-driven study execution.

CellCarta announced a multi-year global strategic partnership with Pillar Biosciences to expand rapid, decentralized tumor profiling for oncology clinical trials. The collaboration combines Pillar Biosciences’ oncoReveal next-generation sequencing (NGS) kitted panels with CellCarta’s global clinical trial testing and biomarker services infrastructure. 

The partnership is designed to enable indication-specific tumor profiling with reduced operational complexity and faster sample-to-report turnaround compared with traditional centralized testing models. The companies said the approach aims to improve enrollment timelines and support biomarker-driven oncology trials, where testing speed and reliability directly impact study execution. 

Under the agreement, sponsors will be able to deploy fit-for-purpose molecular testing aligned to specific study objectives rather than relying on broad testing panels when not required. The companies noted that this approach is intended to reduce operational steps, lower costs, and improve screening efficiency for increasingly complex oncology trial designs. 

The collaboration also supports decentralized testing models by leveraging CellCarta’s global laboratory network and Pillar Biosciences’ standardized kitted NGS panels. This structure is intended to provide consistent testing performance across regions while enabling faster patient identification and enrollment in precision oncology trials. 

“Biomarker-driven oncology trials demand testing strategies that are both operationally efficient and aligned with long-term development goals. Through our partnership with Pillar Biosciences, we combine their streamlined, rapid workflow with our global laboratory execution and deep CDx expertise to support faster enrollment and standardized implementation across regions.” 

Robin Grimwood, Senior Vice President of Genomics at CellCarta